Tower Wealth Partners Inc. Has $419,000 Holdings in Johnson & Johnson (NYSE:JNJ)

Tower Wealth Partners Inc. boosted its position in Johnson & Johnson (NYSE:JNJ) by 15.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,866 shares of the company’s stock after buying an additional 382 shares during the period. Tower Wealth Partners Inc.’s holdings in Johnson & Johnson were worth $419,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Innealta Capital LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $27,000. Christopher J. Hasenberg Inc acquired a new stake in Johnson & Johnson in the first quarter worth $31,000. MFA Wealth Advisors LLC bought a new stake in Johnson & Johnson in the second quarter valued at $43,000. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at about $44,000. Finally, Fairfield Financial Advisors LTD acquired a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $46,000. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of research reports. Sanford C. Bernstein upped their price target on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. The Goldman Sachs Group decreased their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, July 30th. Finally, TD Securities decreased their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $173.21.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $167.02 on Tuesday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $401.96 billion, a PE ratio of 10.41, a PEG ratio of 2.71 and a beta of 0.53. The stock’s 50 day moving average price is $159.98 and its 200-day moving average price is $153.98. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.80 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 2.97%. The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is 30.92%.

Insider Activity

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.